The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Prevalence of Fabry Disease in Female Patients With Late-Onset Hypertrophic Cardiomyopathy
Open accessAbstract
Background— Fabry disease (FD) has been recognized as the cause of left ventricular hypertrophy in 6% of men with late-onset hypertrophic cardiomyopathy (HCM). Although FD is considered a recessive X-linked disorder, affected women are increasingly reported. The aim of our study was to determine the prevalence of FD in female patients with HCM. Methods and Results— Thirty-four consecutive women (mean age, 50±13.6 years) who received an ECG and echocardiographic diagnosis of HCM were submitted to an invasive cardiac study that included a biventricular endomyocardial biopsy. Tissue samples were analyzed for histology and electron microscopy. Peripheral blood activity of α-galactosidase (α-Gal) A was assessed in all patients. None of them had a family history of FD. Histology and electron microscopy showed in 4 patients (12%; mean age, 51.5±3.9 years) the presence of cell vacuoles characterized by the accumulation of glycolipid material organized in concentric lamellar structures, diagnostic for FD. In the remaining patients, histology was consistent with HCM. In all the female carriers, the heart was the only organ clinically involved in the disease, showing concentric hypertrophy in 2 patients, asymmetric hypertrophy in 1, and apical hypertrophy in 1. The α-Gal A enzymatic activity was 44±14% of control values. Genetic analysis showed the presence of α-Gal A gene mutation in all 4 cases. Conclusions— FD may account for up to 12% of females with late-onset HCM. Those heterozygous for FD with left ventricular hypertrophy are potential candidates for enzyme enhancement/replacement therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
Hypertrophic Cardiomyopathy: A Systematic Review
Maron, B. J. (2002) · JAMA · doi:10.1001/jama.287.10.1308 · Cited by 2,224
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
An Atypical Variant of Fabry's Disease in Men with Left Ventricular Hypertrophy
Nakao, S., Takenaka, T., Maeda, M., Kodama, C., Tanaka, A., Tahara, M., Yoshida, A., Kuriyama, M., Hayashibe, H., Sakuraba, H., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508033330504 · Cited by 763
MacDermot, K. D., Holmes, A., & Miners, A. H. (2001) · Journal of Medical Genetics · doi:10.1136/jmg.38.11.769 · Cited by 681
Maron, B. J., Gottdiener, J. S., & Epstein, S. E. (1981) · The American Journal of Cardiology · doi:10.1016/0002-9149(81)90068-0 · Cited by 607
α-Galactosidase A deficiency. Fabry disease
Desnick, R. J. (2001) · Cited by 605
Prevalence of Anderson-Fabry Disease in Male Patients With Late Onset Hypertrophic Cardiomyopathy
Sachdev, B., Takenaka, T., Teraguchi, H., Tei, C., Lee, P., McKenna, W. J., & Elliott, P. M. (2002) · Circulation · doi:10.1161/01.cir.0000012626.81324.38 · Cited by 570
Age- and tissue-specific variation of X chromosome inactivation ratios in normal women
Sharp, A., Robinson, D., & Jacobs, P. (2000) · Human Genetics · doi:10.1007/s004390000382 · Cited by 404
Weidemann, F., Breunig, F., Beer, M., Sandstede, J., Turschner, O., Voelker, W., Ertl, G., Knoll, A., Wanner, C., & Strotmann, J. M. (2003) · Circulation · doi:10.1161/01.cir.0000091253.71282.04 · Cited by 389
Cited by
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e2bd · Cited by 2,104
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy
Marian, A. J., & Braunwald, E. (2017) · Circulation Research · doi:10.1161/circresaha.117.311059 · Cited by 1,403
2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.011 · Cited by 1,276
Gersh, B. J., Maron, B. J., Bonow, R. O., Dearani, J. A., Fifer, M. A., Link, M. S., Naidu, S. S., Nishimura, R. A., Ommen, S. R., Rakowski, H., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318223e230 · Cited by 818
Fabry disease: Guidelines for the evaluation and management of multi-organ system involvement
Eng, C. M., Germain, D. P., Banikazemi, M., Warnock, D. G., Wanner, C., Hopkin, R. J., Bultas, J., Lee, P., Sims, K., Brodie, S. E., et al. (2006) · Genetics in Medicine · doi:10.1097/01.gim.0000237866.70357.c6 · Cited by 411
Metadata
- Authors
- Chimenti, C., Pieroni, M., Morgante, E., Antuzzi, D., Russo, A., Russo, M. A., Maseri, A., & Frustaci, A.
- Venue
- Circulation
- Published
- 2004-08-31
- Volume
- 110
- Issue
- 9
- Pages
- 1047-1053
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2079316384
- Cited by
- 271
- References
- 15
- FWCI
- 7.03
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of Fabry Disease in Female Patients With Late-Onset Hypertrophic Cardiomyopathy. https://app.cochat.ai/papers/10.1161/01.cir.0000139847.74101.03
- The paper
- Chimenti, C., Pieroni, M., Morgante, E., Antuzzi, D., Russo, A., Russo, M. A., Maseri, A., & Frustaci, A. (2004). Prevalence of Fabry Disease in Female Patients With Late-Onset Hypertrophic Cardiomyopathy. Circulation. https://doi.org/10.1161/01.cir.0000139847.74101.03
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.